2027 Star Ratings: What Worked, What Didn’t, and What MA Plans Do Next
The 2027 Medicare Advantage Star Ratings arrive at a point when plans have less room for investments that fail to produce meaningful return. The results offer a fresh opportunity to separate the strategies that moved performance from those that consumed significant resources without enough impact.
Where did plans see meaningful movement, and what drove it? Which measures, member populations and interventions proved most responsive, and where did substantial effort fail to change the outcome? As Stars competes with medical cost, risk adjustment, benefits, retention and growth for the same resources, the larger question is where plans can still exert meaningful influence and which opportunities are worth pursuing.
In this Bright Spots in Healthcare discussion, Medicare Advantage leaders will examine what the 2027 results tell them to do next: where they are doubling down, where they are changing course, and how they are deciding which performance opportunities warrant continued investment. The conversation will focus on the strategies and operating decisions behind the results, what leaders learned from what worked and what did not, and what they are willing to deprioritize to create room for the priorities most likely to matter in the next cycle.